Sex-Specific Effects of Anxiety on Cognition and Activity-Dependent Neural Networks: Insights from (Female) Mice and (Wo)Men.

TitleSex-Specific Effects of Anxiety on Cognition and Activity-Dependent Neural Networks: Insights from (Female) Mice and (Wo)Men.
Publication TypeJournal Article
Year of Publication2023
AuthorsHunsberger HC, Lee S, Jin M, Lanio M, Whye A, Cha J, Scarlata M, Jayaseelan K, Denny CA
JournalbioRxiv
Date Published2023 Jul 10
Abstract

INTRODUCTION: Neuropsychiatric symptoms (NPS), such as depression and anxiety, are observed in 90% of Alzheimer's disease (AD) patients, two-thirds of whom are women. NPS usually manifest long before AD onset creating a therapeutic opportunity. Here, we examined the impact of anxiety on AD progression and the underlying brain-wide neuronal mechanisms.

METHODS: To gain mechanistic insight into how anxiety impacts AD progression, we performed a cross-sectional analysis on mood, cognition, and neural activity utilizing the ArcCreERT2 x enhanced yellow fluorescent protein (eYFP) x APP/PS1 (AD) mice. The ADNI dataset was used to determine the impact of anxiety on AD progression in human subjects.

RESULTS: Female AD mice exhibited anxiety-like behavior and cognitive decline at an earlier age than control (Ctrl) mice and male mice. Brain-wide analysis of c-Fos+ revealed changes in regional correlations and overall network connectivity in AD mice. Sex-specific memory trace changes were observed; female AD mice exhibited impaired memory traces in dorsal CA3 (dCA3), while male AD mice exhibited impaired memory traces in the dorsal dentate gyrus (dDG). In the ADNI dataset, anxiety predicted transition to dementia. Female subjects positive for anxiety and amyloid transitioned more quickly to dementia than male subjects.

CONCLUSIONS: While future studies are needed to understand whether anxiety is a predictor, a neuropsychiatric biomarker, or a comorbid symptom that occurs during disease onset, these results suggest that AD network dysfunction is sexually dimorphic, and that personalized medicine may benefit male and female AD patients rather than a one size fits all approach.

DOI10.1101/2023.07.07.548180
Alternate JournalbioRxiv
PubMed ID37503264
PubMed Central IDPMC10369916
Grant ListR00 AG059953 / AG / NIA NIH HHS / United States
U01 AG024904 / AG / NIA NIH HHS / United States
R24 AG061421 / AG / NIA NIH HHS / United States
K99 AG059953 / AG / NIA NIH HHS / United States
DP5 OD017908 / OD / NIH HHS / United States
R01 HD101402 / HD / NICHD NIH HHS / United States
R21 AG064774 / AG / NIA NIH HHS / United States
R56 AG058661 / AG / NIA NIH HHS / United States
T32 MH015174 / MH / NIMH NIH HHS / United States

Person Type: